PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of st...

Full description

Bibliographic Details
Main Authors:	A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	multiple myeloma bendamustine pharmacoeconomics
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/64

Similar Items

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of Flemoclav Solutab® use in adult patients with acute sinusitis in routine outpatient clinical practice in Russia
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of the use of botulinum toxin in the treatment of poststroke spasticity
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital
by: A. S. Kolbin, et al.
Published: (2015-03-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Current and Novel Alkylators in Multiple Myeloma
by: Fredrik Schjesvold, et al.
Published: (2021-05-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity
by: A. R. Kasimova, et al.
Published: (2022-11-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Pharmacoeconomic analysis of botulinum toxin in complex therapy for cerebral palsy
by: A. S. Kolbin, et al.
Published: (2018-06-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
by: Ana-Alicia López-Iglesias, et al.
Published: (2017-06-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
by: A. V. Pavlysh, et al.
Published: (2015-03-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic effectiveness of phytotherapy in complex treatment of pyelonephritis
by: V. V. Ivanov, et al.
Published: (2015-04-01)

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation
by: A. A. Kurylev, et al.
Published: (2018-05-01)

Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
by: LI Shunping, et al.
Published: (2022-10-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Pharmacoeconomic aspects of COVID-19 treatment
by: I. V. Rogova, et al.
Published: (2021-10-01)

PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review
by: T. S. Romanenko, et al.
Published: (2015-09-01)

Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer
by: A. A. Tryakin, et al.
Published: (2018-11-01)

Pharmacoeconomics in Africa: needs, prospect and challenges
by: Temitope Ben-Ajepe, et al.
Published: (2021-12-01)

Outlook of Pharmacoeconomics and its status in Nepal
by: Sabita Paudel
Published: (2018-03-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment
by: Milewska S, et al.
Published: (2021-09-01)

Development of a pharmacoeconomic registry: an example using hormonal contraceptives
by: Annesha White, et al.
Published: (2021-03-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016
by: Gomon Yu.M., et al.
Published: (2017-08-01)

PHARMACOECONOMIC ANALYSIS OF EFFICACY OF DIFFERENT MODES OF ANTIBIOTIC PROPHYLAXIS IN CHOLECYSTECTOMY
by: A. N. Poborskiy, et al.
Published: (2016-10-01)

PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE
by: E. I. Tarlovskaya, et al.
Published: (2015-09-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
by: V. A. Chibilyaev, et al.
Published: (2015-03-01)

Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
by: A S Kolbin, et al.
Published: (2018-03-01)

Pharmacoeconomic analysis of the use of movalis (meloxicam) in patients with nonspecific back pain
by: O. N. Gerasimova, et al.
Published: (2011-12-01)

PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION
by: R. I. Yagudina, et al.
Published: (2015-03-01)